{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:12:13Z","timestamp":1783743133450,"version":"3.55.0"},"reference-count":26,"publisher":"Japanese Circulation Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,7,10]]},"DOI":"10.1253\/circrep.cr-26-0017","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:09:35Z","timestamp":1781129375000},"page":"1051-1061","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Predictors of New-Onset Heart Failure After Catheter Ablation for Atrial Fibrillation in Patients With a Preserved Ejection Fraction"],"prefix":"10.1253","volume":"8","author":[{"given":"Masahiro","family":"Hisaoka","sequence":"first","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Yoshiga","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ishiguchi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Division of Laboratory, Yamaguchi University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goki","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Omuro","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Science for Heart Failure in the Elderly, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoaki","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Verhaert DVM, Brunner-La Rocca HP, van Veldhuisen DJ, Vernooy K. The bidirectional interaction between atrial fibrillation and heart failure: Consequences for the management of both diseases. <i>Europace<\/i> 2021; 23: ii40\u2013ii45, doi:10.1093\/europace\/euaa368.","DOI":"10.1093\/europace\/euaa368"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS, et al.; ESC-HFA HF Long-Term Registry Investigators. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: A report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. <i>Eur Heart J<\/i> 2018; 39: 4277\u20134284, doi:10.1093\/eurheartj\/ehy626.","DOI":"10.1093\/eurheartj\/ehy626"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. <i>Circulation<\/i> 2003; 107: 2920\u20132925, doi:10.1161\/01.CIR.0000072767.89944.6E.","DOI":"10.1161\/01.CIR.0000072767.89944.6E"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: Temporal associations and differences in preserved versus reduced ejection fraction. <i>Circulation<\/i> 2016; 133: 484\u2013492, doi:10.1161\/CIRCULATIONAHA.115.018614.","DOI":"10.1161\/CIRCULATIONAHA.115.018614"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. <i>N Engl J Med<\/i> 2008; 358: 2667\u20132677, doi:10.1056\/NEJMoa0708789.","DOI":"10.1056\/NEJMoa0708789"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II study). <i>Heart<\/i> 2009; 95: 924\u2013930, doi:10.1136\/hrt.2008.158931.","DOI":"10.1136\/hrt.2008.158931"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al.; EAST-AFNET 4 Trial Investigators. Early rhythm-control therapy in patients with atrial fibrillation. <i>N Engl J Med<\/i> 2020; 383: 1305\u20131316, doi:10.1056\/NEJMoa2019422.","DOI":"10.1056\/NEJMoa2019422"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al.; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. <i>N Engl J Med<\/i> 2018; 378: 417\u2013427, doi:10.1056\/NEJMoa1707855.","DOI":"10.1056\/NEJMoa1707855"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: Results from the RAFT-AF trial. <i>Circulation<\/i> 2022; 145: 1693\u20131704, doi:10.1161\/CIRCULATIONAHA.121.057095.","DOI":"10.1161\/CIRCULATIONAHA.121.057095"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Gu G, Wu J, Gao X, Liu M, Jin C, Xu Y. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction: A meta-analysis. <i>Clin Cardiol<\/i> 2022; 45: 786\u2013793, doi:10.1002\/clc.23841.","DOI":"10.1002\/clc.23841"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al.; CABANA Investigators. Ablation versus drug therapy for atrial fibrillation in heart failure: Results from the CABANA trial. <i>Circulation<\/i> 2021; 143: 1377\u20131390, doi:10.1161\/CIRCULATIONAHA.120.050991.","DOI":"10.1161\/CIRCULATIONAHA.120.050991"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Ishiguchi H, Yoshiga Y, Shimizu A, Fukuda M, Omuro A, Hisaoka M, et al. Novel method for risk stratification of major adverse clinical events using pre- and post-ablation left atrial volume index in patients with persistent atrial fibrillation. <i>Circ Rep<\/i> 2024; 6: 415\u2013423, doi:10.1253\/circrep.CR-24-0062.","DOI":"10.1253\/circrep.CR-24-0062"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Brachmann J, Sohns C, Andresen D, Siebels J, Sehner S, Boersma L, et al. Atrial fibrillation burden and clinical outcomes in heart failure: The CASTLE-AF trial. <i>JACC Clin Electrophysiol<\/i> 2021; 7: 594\u2013603, doi:10.1016\/j.jacep.2020.11.021.","DOI":"10.1016\/j.jacep.2020.11.021"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kawaji T, Shizuta S, Aizawa T, Yamagami S, Kato S, Yokomatsu T, et al. Impact of catheter ablation for atrial fibrillation on cardiac disorders in patients with coexisting heart failure. <i>ESC Heart Fail<\/i> 2021; 8: 670\u2013679, doi:10.1002\/ehf2.13160.","DOI":"10.1002\/ehf2.13160"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Ishiguchi H, Yoshiga Y, Shimizu A, Fukuda M, Hisaoka M, Hashimoto S, et al. Association between the atrial tachyarrhythmia recurrence period and long-term major adverse clinical events following catheter ablation for atrial fibrillation. <i>Int J Cardiol Heart Vasc<\/i> 2023; 47: 101228, doi:10.1016\/j.ijcha.2023.101228.","DOI":"10.1016\/j.ijcha.2023.101228"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, et al.; Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS\/JHFS 2025 Guideline on diagnosis and treatment of heart failure. <i>Circ J<\/i> 2025; 89: 1278\u20131444, doi:10.1253\/circj.CJ-25-0002.","DOI":"10.1253\/circj.CJ-25-0002"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Yoshiga Y, Shimizu A, Ueyama T, Ono M, Fukuda M, Fumimoto T, et al. Strict sequential catheter ablation strategy targeting the pulmonary veins and superior vena cava for persistent atrial fibrillation. <i>J Cardiol<\/i> 2018; 72: 128\u2013134, doi:10.1016\/j.jjcc.2018.01.004.","DOI":"10.1016\/j.jjcc.2018.01.004"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Yoshiga Y, Okamoto T, Shimizu A, Ueyama T, Ono M, Mito T, et al. Correlation between asymptomatic gastroesophageal excessive transmural injury after pulmonary vein isolation and a bonus freeze protocol using the second-generation 28-mm cryoballoon for paroxysmal atrial fibrillation. <i>J Cardiol<\/i> 2019; 74: 494\u2013500, doi:10.1016\/j.jjcc.2019.05.008.","DOI":"10.1016\/j.jjcc.2019.05.008"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Ishiguchi H, Yoshiga Y, Shimizu A, Ueyama T, Ono M, Fukuda M, et al. Impact of atrial tachyarrhythmia recurrence on the development of long-term adverse clinical events following catheter ablation in patients with atrial fibrillation with systolic impairment: A single-center observational study. <i>J Am Heart Assoc<\/i> 2022; 11: e023640, doi:10.1161\/JAHA.121.023640.","DOI":"10.1161\/JAHA.121.023640"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Ishiguchi H, Yoshiga Y, Shimizu A, Ueyama T, Fukuda M, Kato T, et al. Long-term events following catheter-ablation for atrial fibrillation in heart failure with preserved ejection fraction. <i>ESC Heart Fail<\/i> 2022; 9: 3505\u20133518, doi:10.1002\/ehf2.14079.","DOI":"10.1002\/ehf2.14079"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al.; CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial. <i>JAMA<\/i> 2019; 321: 1261\u20131274, doi:10.1001\/jama.2019.0693.","DOI":"10.1001\/jama.2019.0693"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. <i>N Engl J Med<\/i> 2019; 381: 1995\u20132008, doi:10.1056\/NEJMoa1911303.","DOI":"10.1056\/NEJMoa1911303"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. <i>N Engl J Med<\/i> 2021; 385: 1451\u20131461, doi:10.1056\/NEJMoa2107038.","DOI":"10.1056\/NEJMoa2107038"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med<\/i> 2014; 371: 993\u20131004, doi:10.1056\/NEJMoa1409077.","DOI":"10.1056\/NEJMoa1409077"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. <i>N Engl J Med<\/i> 2019; 381: 1609\u20131620, doi:10.1056\/NEJMoa1908655.","DOI":"10.1056\/NEJMoa1908655"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. <i>N Engl J Med<\/i> 2011; 364: 11\u201321, doi:10.1056\/NEJMoa1009.","DOI":"10.1056\/NEJMoa1009492"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/7\/8_CR-26-0017\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:28:12Z","timestamp":1783740492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/7\/8_CR-26-0017\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-26-0017","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"CR-26-0017"}}